Merck & Co., Inc. (MRK) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | 3.17B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $3.17B | (m) |
| 2026-03-31 | (m) | $8.94B | (m) |
| 2025-12-31 | (m) | $18.25B | (m) |
| 2025-09-30 | (m) | $19.03B | (m) |
| 2025-06-30 | (m) | $16.41B | (m) |
| 2025-03-31 | (m) | $17.43B | (m) |
| 2024-12-31 | (m) | $17.12B | (m) |
| 2024-09-30 | (m) | $12.15B | (m) |
| 2024-06-30 | (m) | $13.74B | (m) |
| 2024-03-31 | (m) | $2.31B | (m) |
| 2023-12-31 | (m) | $365.00M | (m) |
| 2023-09-30 | (m) | $4.61B | (m) |
| 2023-06-30 | (m) | $3.11B | (m) |
| 2023-03-31 | (m) | $13.03B | (m) |
| 2022-12-31 | (m) | $14.52B | (m) |
| 2022-09-30 | (m) | $15.26B | (m) |
| 2022-06-30 | (m) | $16.58B | (m) |
| 2022-03-31 | (m) | $14.18B | (m) |
| 2021-12-31 | (m) | $13.05B | (m) |
| 2021-09-30 | (m) | $7.20B | (m) |
| 2021-06-30 | (m) | $5.57B | (m) |
| 2021-03-31 | (m) | $7.03B | (m) |
| 2020-12-31 | (m) | $7.07B | (m) |
| 2020-09-30 | (m) | $11.52B | (m) |
| 2020-06-30 | (m) | $10.48B | (m) |
| 2020-03-31 | (m) | $10.15B | (m) |
| 2019-12-31 | (m) | $9.84B | (m) |
| 2019-09-30 | (m) | $9.31B | (m) |
| 2019-06-30 | (m) | $9.36B | (m) |
| 2019-03-31 | (m) | $8.40B | (m) |
| 2018-12-31 | (m) | $6.22B | (m) |
| 2018-09-30 | (m) | $3.35B | (m) |
| 2018-06-30 | (m) | $1.34B | (m) |
| 2018-03-31 | (m) | $1.58B | (m) |
| 2017-12-31 | (m) | $2.39B | (m) |
| 2017-09-30 | (m) | $2.85B | (m) |
| 2017-06-30 | (m) | $5.09B | (m) |
| 2017-03-31 | (m) | $4.35B | (m) |
| 2016-12-31 | (m) | $3.92B | (m) |
| 2016-09-30 | (m) | $5.49B | (m) |
| 2016-06-30 | (m) | $5.13B | (m) |
| 2016-03-31 | (m) | $4.61B | (m) |
| 2015-12-31 | (m) | $4.44B | (m) |
| 2015-09-30 | (m) | $10.78B | (m) |
| 2015-06-30 | (m) | $9.85B | (m) |
| 2015-03-31 | (m) | $11.17B | (m) |
| 2014-12-31 | (m) | $11.92B | (m) |
| 2014-09-30 | (m) | $5.38B | (m) |
| 2014-06-30 | (m) | $5.61B | (m) |
| 2014-03-31 | (m) | $4.52B | (m) |
| 2013-12-31 | (m) | $4.40B | (m) |
| 2013-09-30 | (m) | $4.53B | (m) |
| 2013-06-30 | (m) | $5.14B | (m) |
| 2013-03-31 | (m) | $6.02B | (m) |
| 2012-12-31 | (m) | $6.17B | (m) |
| 2012-09-30 | (m) | $6.77B | (m) |
| 2012-06-30 | (m) | $6.74B | (m) |
| 2012-03-31 | (m) | $6.97B | (m) |
| 2011-12-31 | (m) | $6.27B | (m) |
| 2011-09-30 | (m) | $4.23B | (m) |
| 2011-06-30 | (m) | $2.88B | (m) |
| 2011-03-31 | (m) | $1.60B | (m) |
| 2010-12-31 | (m) | $861.00M | (m) |
| 2010-09-30 | (m) | $7.89B | (m) |
| 2010-06-30 | (m) | $10.97B | (m) |
| 2010-03-31 | (m) | $11.78B | (m) |
| 2009-12-31 | (m) | $12.90B | (m) |
| 2009-09-30 | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) |
| 2008-12-31 | (m) | $7.81B | (m) |
| 2008-09-30 | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) |
| 2007-12-31 | (m) | $3.28B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |